Postdoctoral fellow. Charles Ornstein is a senior editor at ProPublica.
Postdoctoral Fellow. Agata (Aggie) Bielska.
, Patents arising from Thompson’s research describing the co-stimulatory/inhibitory properties of CD28/CTLA-4, in collaboration with Carl June and Jeffrey Bluestone, were licensed for the development of Abatacept (Orencia) for autoimmune diseases and for use in T cell cloning and CAR T cell production. priorities: quality patient care, faculty, scientists and staff,” Dr. Thompson said in a memo sent to the hospital staff. Thompson identified the evolutionary duplication of CD28 into CD28 and CTLA-4 and demonstrated that CTLA4 had an inhibitory effect on immune activation. Dr. Thompson, 65, received $300,000 in compensation from Merck in 2017, according to company financial filings. (2019).
The University of Pennsylvania filed the suit against Dr. Craig B. Thompson, claiming he improperly used research done at the university to start a pharmaceutical company. Memorial Sloan Kettering’s Chief Executive Resigns From Merck’s Board of Directors.
(2020). , Thompson elucidated processes on the genes that control programmed cell death or apoptosis. From 1993 until he joined the University of Pennsylvania, he was affiliated with the University of Chicago, where he was professor of medicine, a Howard Hughes investigator, and director of the Gwen Knapp Center for Lupus and Immunology Research. Santosha Vardhana. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. Zhu, J., Berisa, M., Schwörer, S., Qin, W., Cross, J. R., & Thompson, C. B. , In December 2011, The University and its Abramson Family Cancer Research Institute sued Thompson after his move to Memorial Sloan Kettering, charging that he had made use of research conducted at the University of Pennsylvania to start a biotechnology company, Agios Pharmaceuticals that Thompson had co-founded in 2007 while still at the University. He was paid $70,000 in cash by Charles River in 2017, plus $215,050 in stock. n/a- Not available.
His group discovered the first Bcl-2 homolog to be identified, Bcl-Xl, and described the first BH3-only containing regulatory family member, Bcl-xS. After completing his training, Thompson became a physician at the National Naval Medical Center in Bethesda, Maryland, and an assistant professor of medicine at the Uniformed Services University of the Health Sciences. SOURCES: IRS Form 990, annual report or statement of individual nonprofit. Craig Thompson resigns from two corporate boards as MSK crisis shifts to board roles.